Blocking Blog calprotectin elisa Elisa hama antibodies hmgb1 elisa iron assay Isotype p24 elisa Pcr pge2 elisa plc gamma 2 rna Serum tbars assay kit tdgf1 triglyceride assay upp1 Vector
Streptolysin O concentration and activity is central to in vivo phenotype and disease outcome in Group A Streptococcus infection
Group A Streptoccocus (GAS) is among the many most numerous of all human pathogens, accountable for a variety of medical manifestations, from delicate superficial infections akin to pharyngitis to severe invasive infections akin to necrotising fasciitis and sepsis.
The drivers of those completely different illness phenotypes aren’t recognized. The GAS cholesterol-dependent cytolysin, Streptolysin O (SLO), has properly established cell and tissue harmful exercise. We investigated the position of SLO in figuring out illness final result in vivo, by utilizing two completely different medical lineages; the not too long ago emerged hypervirulent outbreak emm kind 32.2 strains, which end in sepsis, and the emm kind 1.Zero strains which trigger septic arthritis.
Utilizing clinically related in vivo mouse fashions of sepsis and a novel septic arthritis mannequin, we discovered that the quantity and exercise of SLO was important in figuring out the course of an infection. The emm kind 32.2 pressure produced giant portions of extremely haemolytic SLO that resulted in speedy growth of sepsis.
Against this, the lowered focus and decrease haemolytic exercise of emm kind 1.Zero SLO led to translocation of micro organism from blood to joints. Importantly, sepsis related strains that have been attenuated by deletion or inhibition of SLO, then additionally translocated to the joint, confirming the important thing position of SLO in figuring out an infection area of interest.
Our findings show that SLO is vital to in vivo phenotype and illness final result. Cautious consideration needs to be given to novel remedy or vaccination methods that focus on SLO. While neutralising SLO exercise might cut back extreme invasive illness, it has the potential to advertise continual inflammatory circumstances akin to septic arthritis.
A longitudinal sampling research of transcriptomic and epigenetic profiles in sufferers with thrombocytopenia syndrome’
Extreme fever with thrombocytopenia syndrome (SFTS) is a novel tick-borne infectious illness attributable to a brand new kind of SFTS virus (SFTSV). Right here, a longitudinal sampling research is performed to discover the variations in transcript ranges after SFTSV an infection, and to characterize the transcriptomic and epigenetic profiles of hospitalized sufferers.
The outcomes reveal important modifications within the mRNA expression of sure genes from onset to restoration. Furthermore, m6A-seq reveals that sure genes associated with immune regulation could also be regulated by m6A.
Moreover the routine checks akin to platelet counts, serum ALT and AST ranges testing, distinct modifications in myocardial enzymes, coagulation perform, and irritation are properly correlated with the medical knowledge and sequencing knowledge, suggesting that medical practitioners ought to monitor the above indicators to trace illness development and information personalised therapy.
On this research, the transcript modifications and RNA modification might lend a contemporary perspective to our understanding of the SFTSV and play a major position within the discovery of medication for efficient therapy of this illness.
Optimising classification of Parkinson’s illness primarily based on motor, olfactory, neuropsychiatric and sleep options
Olfactory loss, motor impairment, anxiousness/despair, and REM-sleep behaviour dysfunction (RBD) are prodromal Parkinson’s illness (PD) options. PD threat prediction fashions sometimes dichotomize take a look at outcomes and apply probability ratios (LRs) to scores above and under cut-offs. We examine whether or not LRs for particular take a look at values might improve classification between PD and controls.
PD affected person knowledge on odor (UPSIT), attainable RBD (RBD Screening Questionnaire), and anxiousness/despair (LADS) have been taken from the Monitoring Parkinson’s research (n = 1046). For motor impairment (BRAIN take a look at) in PD circumstances, revealed knowledge have been supplemented (n = 87). Management knowledge (HADS for anxiousness/despair) have been taken from the PREDICT-PD pilot research (n = 1314).
UPSIT, RBDSQ, and anxiousness/despair knowledge have been analysed utilizing logistic regression to find out which gadgets have been related to PD. Gaussian distributions have been fitted to BRAIN take a look at scores. LRs have been calculated from logistic regression fashions or rating distributions. False-positive charges (FPRs) for specified detection charges (DRs) have been calculated.
Sixteen odours have been related to PD; LRs for this set ranged from 0.005 to 5511. Six RBDSQ and 7 anxiousness/despair questions have been related to PD; LRs ranged from 0.35 to 69 and from 0.002 to 402, respectively. BRAIN take a look at LRs ranged from 0.16 to 1311. For a 70% DR, the FPR was 2.4% for the 16 odours, 4.6% for anxiousness/despair, 16.0% for the BRAIN take a look at, and 20.0% for the RBDSQ.
Particular choices of (prodromal) PD marker options reasonably than dichotomized marker take a look at outcomes optimize PD classification. Such optimized classification fashions might enhance the power of algorithms to detect prodromal PD; nevertheless, potential research are wanted to analyze their worth for PD-prediction fashions.
Sleep issues in ache sufferers coming into tertiary ache care: the position of pain-related anxiousness, medicine use, self-reported ailments, and sleep issues
Continual ache and sleep issues regularly co-occur. Ache itself disturbs sleep, however different elements can also contribute to sleep issues in ache sufferers. This cross-sectional research of 473 sufferers (69.9% feminine, imply age 47 years) coming into tertiary ache administration in contrast usually sleeping ache sufferers with these having recurring sleep issues to find out the connection between ache and sleep.
Teams have been in contrast for ache and ache aetiology, pain-related anxiousness, childhood adversities, use of sleep and ache medicines, self-reported ailments, and sleep issues. Additional, the affiliation of pain-related anxiousness (cognitive anxiousness, escape/avoidance, worry, and physiological anxiousness) with extra disturbing sleep issues was investigated in the entire cohort.
The primary outcomes have been that these with sleep issues extra typically reported a number of well being circumstances than these sleeping usually (despair 31.6% vs 5.0%; angina pectoris 6.5% vs 0.0%; bronchial asthma 19.6% vs 1.7%; low again issues 55.1% vs 23.3%; joint illness apart from rheumatoid arthritis 32.3% vs 18.3%).
Accumulations of 5 or extra childhood adversities have been extra typically current in these with sleep issues. Stressed legs signs have been extra frequent in these with sleep issues than these sleeping usually (33.2% vs 11.7%). Sufferers having sleep issues reported extra use of sleep and ache medicines than these sleeping usually. Findings about pain-related anxiousness recommend physiological reactions as important elements for elevated sleep disturbances. These elements have to be addressed within the administration of the comorbidity of ache and sleep issues and analysis to grasp mechanisms in these is sorely wanted.
Regulation and Position of αE Integrin and Intestine Homing Integrins in Migration and Retention of Intestinal Lymphocytes throughout Inflammatory Bowel Illness
Concentrating on interactions between α4β7 integrin and endothelial adhesion molecule MAdCAM-1 to inhibit lymphocyte migration to the gastrointestinal tract is an efficient remedy in inflammatory bowel illness (IBD). Following lymphocyte entry into the mucosa, a subset of those cells expresses αEβ7 integrin, which is expressed on proinflammatory lymphocytes, to extend cell retention.
The elements governing lymphocyte migration into the intestinal mucosa and αE integrin expression in wholesome topics and IBD sufferers stay incompletely understood. We evaluated modifications in elements concerned in lymphocyte migration and differentiation inside tissues.
Each ileal and colonic tissue from lively IBD sufferers confirmed upregulation of ICAM-1, VCAM-1, and MAdCAM-1 on the gene and protein ranges in contrast with wholesome topics and/or inactive IBD sufferers. β1 and β7 integrin expression on circulating lymphocytes was comparable throughout teams.
TGF-β1 therapy induced expression of αE on each β7+ and β7– T cells, suggesting that cells coming into the mucosa independently of MAdCAM-1/α4β7 can grow to be αEβ7+ ITGAE gene polymorphisms didn’t alter protein induction following TGF-β1 stimulation.
Elevated phospho-SMAD3, which is immediately downstream of TGF-β, and elevated TGF-β-responsive gene expression have been noticed within the colonic mucosa of IBD sufferers. Lastly, in vitro stimulation experiments confirmed that baseline β7 expression had little impact on cytokine, chemokine, transcription issue, and effector molecule gene expression in αE+ and αE– T cells.
ARVCF Oxidase antibody |
|||
| 20R-2590 | Fitzgerald | 100 uL | EUR 612 |
|
Description: Guinea Pig polyclonal ARVCF Oxidase antibody |
|||
Anti-ARVCF (5D2) |
|||
| YF-MA10064 | Abfrontier | 100 ug | EUR 435.6 |
|
Description: Mouse monoclonal to ARVCF |
|||
Human ARVCF shRNA Plasmid |
|||
| 20-abx950307 | Abbexa |
|
|
Mouse ARVCF shRNA Plasmid |
|||
| 20-abx969243 | Abbexa |
|
|
ARVCF ELISA KIT|Human |
|||
| EF004632 | Lifescience Market | 96 Tests | EUR 826.8 |
Human ARVCF ELISA KIT |
|||
| ELI-34376h | Lifescience Market | 96 Tests | EUR 988.8 |
Mouse Arvcf ELISA KIT |
|||
| ELI-49351m | Lifescience Market | 96 Tests | EUR 1038 |
ARVCF Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV631424 | ABM | 1.0 ug DNA | EUR 1626 |
ARVCF Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV631425 | ABM | 1.0 ug DNA | EUR 1695.6 |
ARVCF Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV631426 | ABM | 1.0 ug DNA | EUR 1695.6 |
ARVCF Protein Vector (Mouse) (pPB-C-His) |
|||
| PV156526 | ABM | 500 ng | EUR 1278 |
ARVCF Protein Vector (Mouse) (pPB-N-His) |
|||
| PV156527 | ABM | 500 ng | EUR 1278 |
ARVCF Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV156528 | ABM | 500 ng | EUR 1278 |
ARVCF Protein Vector (Mouse) (pPM-C-His) |
|||
| PV156529 | ABM | 500 ng | EUR 1278 |
ARVCF Protein Vector (Human) (pPB-C-His) |
|||
| PV063337 | ABM | 500 ng | EUR 973.2 |
ARVCF Protein Vector (Human) (pPB-N-His) |
|||
| PV063338 | ABM | 500 ng | EUR 973.2 |
ARVCF Protein Vector (Human) (pPM-C-HA) |
|||
| PV063339 | ABM | 500 ng | EUR 973.2 |
ARVCF Protein Vector (Human) (pPM-C-His) |
|||
| PV063340 | ABM | 500 ng | EUR 973.2 |
ARVCF Protein Vector (Human) (pPB-His-MBP) |
|||
| PV324102 | ABM | 500 ng | EUR 973.2 |
ARVCF Protein Vector (Human) (pPB-His-GST) |
|||
| PV324103 | ABM | 500 ng | EUR 973.2 |
ARVCF Protein Vector (Rat) (pPB-C-His) |
|||
| PV254798 | ABM | 500 ng | EUR 1399.2 |
ARVCF Protein Vector (Rat) (pPB-N-His) |
|||
| PV254799 | ABM | 500 ng | EUR 1399.2 |
ARVCF Protein Vector (Rat) (pPM-C-HA) |
|||
| PV254800 | ABM | 500 ng | EUR 1399.2 |
ARVCF Protein Vector (Rat) (pPM-C-His) |
|||
| PV254801 | ABM | 500 ng | EUR 1399.2 |
ARVCF sgRNA CRISPR Lentivector set (Human) |
|||
| K0129701 | ABM | 3 x 1.0 ug | EUR 406.8 |
Arvcf sgRNA CRISPR Lentivector set (Mouse) |
|||
| K4629501 | ABM | 3 x 1.0 ug | EUR 406.8 |
Arvcf sgRNA CRISPR Lentivector set (Rat) |
|||
| K7275001 | ABM | 3 x 1.0 ug | EUR 406.8 |
ARVCF Protein Vector (Human) (pPM-N-D-C-HA) |
|||
| PV324104 | ABM | 500 ng | EUR 1216.8 |
ARVCF Protein Vector (Human) (pPM-N-D-C-His) |
|||
| PV324105 | ABM | 500 ng | EUR 1216.8 |
Monoclonal ARVCF Antibody (monoclonal) (M01), Clone: 5D2 |
|||
| APR15063G | Leading Biology | 0.1mg | EUR 580.8 |
|
Description: A Monoclonal antibody against Human ARVCF (monoclonal) (M01). The antibodies are raised in mouse and are from clone 5D2. This antibody is applicable in WB and IHC |
|||
Monoclonal ARVCF Antibody (clone 5D2), Clone: 5D2 |
|||
| APR15077G | Leading Biology | 0.05mg | EUR 633.6 |
|
Description: A Monoclonal antibody against Human ARVCF (clone 5D2). The antibodies are raised in Mouse and are from clone 5D2. This antibody is applicable in WB and IHC-P |
|||
ARVCF sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
| K0129702 | ABM | 1.0 ug DNA | EUR 184.8 |
ARVCF sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
| K0129703 | ABM | 1.0 ug DNA | EUR 184.8 |
ARVCF sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
| K0129704 | ABM | 1.0 ug DNA | EUR 184.8 |
Arvcf sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|||
| K4629502 | ABM | 1.0 ug DNA | EUR 184.8 |
Arvcf sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|||
| K4629503 | ABM | 1.0 ug DNA | EUR 184.8 |
Arvcf sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|||
| K4629504 | ABM | 1.0 ug DNA | EUR 184.8 |
Arvcf sgRNA CRISPR Lentivector (Rat) (Target 1) |
|||
| K7275002 | ABM | 1.0 ug DNA | EUR 184.8 |
Arvcf sgRNA CRISPR Lentivector (Rat) (Target 2) |
|||
| K7275003 | ABM | 1.0 ug DNA | EUR 184.8 |
Arvcf sgRNA CRISPR Lentivector (Rat) (Target 3) |
|||
| K7275004 | ABM | 1.0 ug DNA | EUR 184.8 |
ARVCF 3'UTR Luciferase Stable Cell Line |
|||
| TU001212 | ABM | 1.0 ml | EUR 1672.8 |
Arvcf 3'UTR Luciferase Stable Cell Line |
|||
| TU102177 | ABM | 1.0 ml | Ask for price |
ARVCF 3'UTR GFP Stable Cell Line |
|||
| TU051212 | ABM | 1.0 ml | EUR 1672.8 |
Arvcf 3'UTR Luciferase Stable Cell Line |
|||
| TU200947 | ABM | 1.0 ml | Ask for price |
Arvcf 3'UTR GFP Stable Cell Line |
|||
| TU250947 | ABM | 1.0 ml | Ask for price |
Arvcf 3'UTR GFP Stable Cell Line |
|||
| TU152177 | ABM | 1.0 ml | Ask for price |
Arvcf ELISA Kit| Mouse Armadillo repeat protein deleted in velo |
|||
| EF014236 | Lifescience Market | 96 Tests | EUR 826.8 |
ARVCF sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
| K0129705 | ABM | 3 x 1.0 ug | EUR 451.2 |
Arvcf sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse) |
|||
| K4629505 | ABM | 3 x 1.0 ug | EUR 451.2 |
Arvcf sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat) |
|||
| K7275005 | ABM | 3 x 1.0 ug | EUR 451.2 |
Human Armadillo Repeat Gene Deleted In Velocardiofacial Syndrome (ARVCF) ELISA Kit |
|||
| abx384600-96tests | Abbexa | 96 tests | EUR 1093.2 |
Mouse Armadillo Repeat Gene Deleted In Velocardiofacial Syndrome (ARVCF) ELISA Kit |
|||
| abx388611-96tests | Abbexa | 96 tests | EUR 1093.2 |
ARVCF sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
|||
| K0129706 | ABM | 1.0 ug DNA | EUR 200.4 |
ARVCF sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
|||
| K0129707 | ABM | 1.0 ug DNA | EUR 200.4 |
ARVCF sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
|||
| K0129708 | ABM | 1.0 ug DNA | EUR 200.4 |
Arvcf sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1) |
|||
| K4629506 | ABM | 1.0 ug DNA | EUR 200.4 |
Arvcf sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2) |
|||
| K4629507 | ABM | 1.0 ug DNA | EUR 200.4 |
Arvcf sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3) |
|||
| K4629508 | ABM | 1.0 ug DNA | EUR 200.4 |
Arvcf sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1) |
|||
| K7275006 | ABM | 1.0 ug DNA | EUR 200.4 |
Arvcf sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2) |
|||
| K7275007 | ABM | 1.0 ug DNA | EUR 200.4 |
Arvcf sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3) |
|||
| K7275008 | ABM | 1.0 ug DNA | EUR 200.4 |
Rat Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) ELISA kit |
|||
| E02A1693-192T | BlueGene | 192 tests | EUR 1524 |
|
Description: A competitive ELISA for quantitative measurement of Rat Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Rat Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) ELISA kit |
|||
| E02A1693-48 | BlueGene | 1 plate of 48 wells | EUR 624 |
|
Description: A competitive ELISA for quantitative measurement of Rat Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Rat Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) ELISA kit |
|||
| E02A1693-96 | BlueGene | 1 plate of 96 wells | EUR 822 |
|
Description: A competitive ELISA for quantitative measurement of Rat Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Rabbit Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) ELISA kit |
|||
| E04A1693-192T | BlueGene | 192 tests | EUR 1524 |
|
Description: A competitive ELISA for quantitative measurement of Rabbit Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Rabbit Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) ELISA kit |
|||
| E04A1693-48 | BlueGene | 1 plate of 48 wells | EUR 624 |
|
Description: A competitive ELISA for quantitative measurement of Rabbit Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Rabbit Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) ELISA kit |
|||
| E04A1693-96 | BlueGene | 1 plate of 96 wells | EUR 822 |
|
Description: A competitive ELISA for quantitative measurement of Rabbit Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Pig Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) ELISA kit |
|||
| E07A1693-192T | BlueGene | 192 tests | EUR 1524 |
|
Description: A competitive ELISA for quantitative measurement of Porcine Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Pig Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) ELISA kit |
|||
| E07A1693-48 | BlueGene | 1 plate of 48 wells | EUR 624 |
|
Description: A competitive ELISA for quantitative measurement of Porcine Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Pig Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) ELISA kit |
|||
| E07A1693-96 | BlueGene | 1 plate of 96 wells | EUR 822 |
|
Description: A competitive ELISA for quantitative measurement of Porcine Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Goat Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) ELISA kit |
|||
| E06A1693-192T | BlueGene | 192 tests | EUR 1524 |
|
Description: A competitive ELISA for quantitative measurement of Goat Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Goat Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) ELISA kit |
|||
| E06A1693-48 | BlueGene | 1 plate of 48 wells | EUR 624 |
|
Description: A competitive ELISA for quantitative measurement of Goat Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Goat Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) ELISA kit |
|||
| E06A1693-96 | BlueGene | 1 plate of 96 wells | EUR 822 |
|
Description: A competitive ELISA for quantitative measurement of Goat Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Human Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) ELISA kit |
|||
| E01A1693-192T | BlueGene | 192 tests | EUR 1524 |
|
Description: A competitive ELISA for quantitative measurement of Human Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Human Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) ELISA kit |
|||
| E01A1693-48 | BlueGene | 1 plate of 48 wells | EUR 624 |
|
Description: A competitive ELISA for quantitative measurement of Human Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Human Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) ELISA kit |
|||
| E01A1693-96 | BlueGene | 1 plate of 96 wells | EUR 822 |
|
Description: A competitive ELISA for quantitative measurement of Human Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Mouse Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) ELISA kit |
|||
| E03A1693-192T | BlueGene | 192 tests | EUR 1524 |
|
Description: A competitive ELISA for quantitative measurement of Mouse Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Mouse Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) ELISA kit |
|||
| E03A1693-48 | BlueGene | 1 plate of 48 wells | EUR 624 |
|
Description: A competitive ELISA for quantitative measurement of Mouse Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Mouse Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) ELISA kit |
|||
| E03A1693-96 | BlueGene | 1 plate of 96 wells | EUR 822 |
|
Description: A competitive ELISA for quantitative measurement of Mouse Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Dog Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) ELISA kit |
|||
| E08A1693-192T | BlueGene | 192 tests | EUR 1524 |
|
Description: A competitive ELISA for quantitative measurement of Canine Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Dog Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) ELISA kit |
|||
| E08A1693-48 | BlueGene | 1 plate of 48 wells | EUR 624 |
|
Description: A competitive ELISA for quantitative measurement of Canine Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Dog Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) ELISA kit |
|||
| E08A1693-96 | BlueGene | 1 plate of 96 wells | EUR 822 |
|
Description: A competitive ELISA for quantitative measurement of Canine Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Monkey Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) ELISA kit |
|||
| E09A1693-192T | BlueGene | 192 tests | EUR 1524 |
|
Description: A competitive ELISA for quantitative measurement of Monkey Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Monkey Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) ELISA kit |
|||
| E09A1693-48 | BlueGene | 1 plate of 48 wells | EUR 624 |
|
Description: A competitive ELISA for quantitative measurement of Monkey Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Monkey Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) ELISA kit |
|||
| E09A1693-96 | BlueGene | 1 plate of 96 wells | EUR 822 |
|
Description: A competitive ELISA for quantitative measurement of Monkey Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Guinea pig Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) ELISA kit |
|||
| E05A1693-192T | BlueGene | 192 tests | EUR 1524 |
|
Description: A competitive ELISA for quantitative measurement of Guinea pig Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Guinea pig Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) ELISA kit |
|||
| E05A1693-48 | BlueGene | 1 plate of 48 wells | EUR 624 |
|
Description: A competitive ELISA for quantitative measurement of Guinea pig Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Guinea pig Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) ELISA kit |
|||
| E05A1693-96 | BlueGene | 1 plate of 96 wells | EUR 822 |
|
Description: A competitive ELISA for quantitative measurement of Guinea pig Armadillo repeat protein deleted in velo cardio facial syndrome(ARVCF) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Cas9 Nickase Lentiviral Vector |
|||
| K005 | ABM | 10 ug | EUR 184.8 |
Cas9 Nuclease Lentiviral Vector |
|||
| K002 | ABM | 10 ug | EUR 184.8 |
dCas9-KRAB Lentiviral Vector |
|||
| K203 | ABM | 10 ug | EUR 273.6 |
pLenti-GFP Lentiviral Control Vector |
|||
| LTV-400 | Cell Biolabs | 100 µL | EUR 741.6 |
|
Description: Use this control vector to co-transfect along with lentivirus packaging vectors to make a recombinant control lentivirus. |
|||
pSMPUW-MNDnLacZ Lentiviral Control Vector |
|||
| LTV-402 | Cell Biolabs | 10 µg | EUR 741.6 |
|
Description: Use this control vector to co-transfect along with lentivirus packaging vectors to make a recombinant control lentivirus. |
|||
Cas9 Double Mutant Lentiviral Vector |
|||
| K012 | ABM | 10 ug | EUR 643.2 |
pSMPUW-Puro Lentiviral Expression Vector |
|||
| VPK-212 | Cell Biolabs | 10 µg | EUR 748.8 |
|
Description: Clone your gene of interest into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer. |
|||
pSMPUW-Neo Lentiviral Expression Vector |
|||
| VPK-213 | Cell Biolabs | 10 µg | EUR 748.8 |
|
Description: Clone your gene of interest into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer. |
|||
pSMPUW-Hygro Lentiviral Expression Vector |
|||
| VPK-214 | Cell Biolabs | 10 µg | EUR 748.8 |
|
Description: Clone your gene of interest into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer. |
|||
pSMPUW-GFP-Puro Lentiviral Control Vector |
|||
| LTV-401 | Cell Biolabs | 10 µg | EUR 741.6 |
|
Description: Use this control vector to co-transfect along with lentivirus packaging vectors to make a recombinant control lentivirus. |
|||
pLenti-RFP-Puro Lentiviral Control Vector |
|||
| LTV-403 | Cell Biolabs | 100 µL | EUR 741.6 |
|
Description: Use this control vector to co-transfect along with lentivirus packaging vectors to make a recombinant control lentivirus. |
|||
pSMPUW-GFP-LC3 Lentiviral Expression Vector |
|||
| LTV-801 | Cell Biolabs | 10 µg | EUR 1444.8 |
|
Description: Expression vector contains a fusion of GFP and LC3. A separate GFP control vector is also included. |
|||
ESR1 Lentiviral Vector (Human) (pLenti-II) |
|||
| LV010008 | ABM | 1.0 ug DNA | EUR 379.2 |
pSMPUW Universal Lentiviral Expression Vector (Promoterless) |
|||
| VPK-211 | Cell Biolabs | 10 µg | EUR 748.8 |
|
Description: Clone your gene of interest and a gene-specific promoter into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293T or 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer. |
|||
pSMPUW-IRES-Puro Lentiviral Expression Vector |
|||
| VPK-215 | Cell Biolabs | 10 µg | EUR 748.8 |
|
Description: Clone your gene of interest into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer. |
|||
pSMPUW-IRES-Neo Lentiviral Expression Vector |
|||
| VPK-216 | Cell Biolabs | 10 µg | EUR 748.8 |
|
Description: Clone your gene of interest into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer. |
|||
pSMPUW-IRES-Hygro Lentiviral Expression Vector |
|||
| VPK-217 | Cell Biolabs | 10 µg | EUR 748.8 |
|
Description: Clone your gene of interest into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer. |
|||
pSMPUW-IRES-Blasticidin Lentiviral Expression Vector |
|||
| VPK-219 | Cell Biolabs | 10 µg | EUR 748.8 |
|
Description: Clone your gene of interest into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer. |
|||
ERAF Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810237 | ABM | 1.0 ug DNA | EUR 379.2 |
ERAF Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810241 | ABM | 1.0 ug DNA | EUR 379.2 |
ERAF Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810242 | ABM | 1.0 ug DNA | EUR 379.2 |
C6orf218 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810243 | ABM | 1.0 ug DNA | EUR 379.2 |
C6orf218 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810247 | ABM | 1.0 ug DNA | EUR 379.2 |
C6orf218 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810248 | ABM | 1.0 ug DNA | EUR 379.2 |
BXDC1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810249 | ABM | 1.0 ug DNA | EUR 379.2 |
BXDC1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810253 | ABM | 1.0 ug DNA | EUR 379.2 |
BXDC1 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810254 | ABM | 1.0 ug DNA | EUR 379.2 |
C17orf45 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810255 | ABM | 1.0 ug DNA | EUR 379.2 |
C17orf45 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810259 | ABM | 1.0 ug DNA | EUR 379.2 |
C17orf45 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810260 | ABM | 1.0 ug DNA | EUR 379.2 |
FAM86C Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810261 | ABM | 1.0 ug DNA | EUR 379.2 |
FAM86C Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810265 | ABM | 1.0 ug DNA | EUR 379.2 |
FAM86C Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810266 | ABM | 1.0 ug DNA | EUR 379.2 |
C3orf31 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810267 | ABM | 1.0 ug DNA | EUR 379.2 |
C3orf31 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810271 | ABM | 1.0 ug DNA | EUR 379.2 |
C3orf31 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810272 | ABM | 1.0 ug DNA | EUR 379.2 |
C13orf16 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810279 | ABM | 1.0 ug DNA | EUR 379.2 |
C13orf16 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810283 | ABM | 1.0 ug DNA | EUR 379.2 |
C13orf16 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810284 | ABM | 1.0 ug DNA | EUR 379.2 |
C21ORF55 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810285 | ABM | 1.0 ug DNA | EUR 379.2 |
C21ORF55 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810289 | ABM | 1.0 ug DNA | EUR 379.2 |
C21ORF55 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810290 | ABM | 1.0 ug DNA | EUR 379.2 |
FLJ10357 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810291 | ABM | 1.0 ug DNA | EUR 379.2 |
FLJ10357 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810295 | ABM | 1.0 ug DNA | EUR 379.2 |
FLJ10357 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810296 | ABM | 1.0 ug DNA | EUR 379.2 |
C13orf3 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810297 | ABM | 1.0 ug DNA | EUR 379.2 |
C13orf3 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810301 | ABM | 1.0 ug DNA | EUR 379.2 |
C13orf3 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810302 | ABM | 1.0 ug DNA | EUR 379.2 |
ARL17 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810303 | ABM | 1.0 ug DNA | EUR 379.2 |
ARL17 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810307 | ABM | 1.0 ug DNA | EUR 379.2 |
ARL17 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810308 | ABM | 1.0 ug DNA | EUR 379.2 |
HSPC047 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810309 | ABM | 1.0 ug DNA | EUR 379.2 |
HSPC047 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810313 | ABM | 1.0 ug DNA | EUR 379.2 |
HSPC047 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810314 | ABM | 1.0 ug DNA | EUR 379.2 |
C9orf68 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810315 | ABM | 1.0 ug DNA | EUR 379.2 |
C9orf68 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810319 | ABM | 1.0 ug DNA | EUR 379.2 |
C9orf68 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810320 | ABM | 1.0 ug DNA | EUR 379.2 |
C18orf22 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810321 | ABM | 1.0 ug DNA | EUR 379.2 |
C18orf22 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810325 | ABM | 1.0 ug DNA | EUR 379.2 |
C18orf22 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810326 | ABM | 1.0 ug DNA | EUR 379.2 |
KIAA0774 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810327 | ABM | 1.0 ug DNA | EUR 379.2 |
KIAA0774 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810331 | ABM | 1.0 ug DNA | EUR 379.2 |
KIAA0774 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810332 | ABM | 1.0 ug DNA | EUR 379.2 |
BXDC5 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810333 | ABM | 1.0 ug DNA | EUR 379.2 |
BXDC5 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810337 | ABM | 1.0 ug DNA | EUR 379.2 |
BXDC5 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810338 | ABM | 1.0 ug DNA | EUR 379.2 |
IL8RA Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810339 | ABM | 1.0 ug DNA | EUR 379.2 |
IL8RA Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810343 | ABM | 1.0 ug DNA | EUR 379.2 |
IL8RA Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810344 | ABM | 1.0 ug DNA | EUR 379.2 |
RBM9 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810345 | ABM | 1.0 ug DNA | EUR 379.2 |
RBM9 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810349 | ABM | 1.0 ug DNA | EUR 379.2 |
RBM9 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810350 | ABM | 1.0 ug DNA | EUR 379.2 |
FAM62B Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810351 | ABM | 1.0 ug DNA | EUR 379.2 |
FAM62B Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810355 | ABM | 1.0 ug DNA | EUR 379.2 |
FAM62B Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810356 | ABM | 1.0 ug DNA | EUR 379.2 |
BC013798 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810357 | ABM | 1.0 ug DNA | EUR 379.2 |
BC013798 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810361 | ABM | 1.0 ug DNA | EUR 379.2 |
BC013798 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810362 | ABM | 1.0 ug DNA | EUR 379.2 |
RTCD1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810363 | ABM | 1.0 ug DNA | EUR 379.2 |
RTCD1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810367 | ABM | 1.0 ug DNA | EUR 379.2 |
RTCD1 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810368 | ABM | 1.0 ug DNA | EUR 379.2 |
TTC15 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810369 | ABM | 1.0 ug DNA | EUR 379.2 |
TTC15 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810373 | ABM | 1.0 ug DNA | EUR 379.2 |
TTC15 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810374 | ABM | 1.0 ug DNA | EUR 379.2 |
RAD51L1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810375 | ABM | 1.0 ug DNA | EUR 379.2 |
RAD51L1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810379 | ABM | 1.0 ug DNA | EUR 379.2 |
RAD51L1 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810380 | ABM | 1.0 ug DNA | EUR 379.2 |
TSP50 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810381 | ABM | 1.0 ug DNA | EUR 379.2 |
TSP50 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810385 | ABM | 1.0 ug DNA | EUR 379.2 |
These findings recommend cell migration to the intestine mucosa could also be altered in IBD and α4β7–, and α4β7+ T cells might upregulate αEβ7 in response to TGF-β as soon as throughout the intestine mucosa.
